DOCSLIB.ORG

Establishment of a Novel in Vitro Model for Predicting Incidence and Severity of Microtubule-Targeting Agent-Induced Peripheral Neuropathy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Establishment of a Novel in Vitro Model for Predicting Incidence and Severity of Microtubule-Targeting Agent-Induced Peripheral Neuropathy ANTICANCER RESEARCH 35: 6431-6438 (2015) Establishment of a Novel In Vitro Model for Predicting Incidence and Severity of Microtubule-targeting Agent-induced Peripheral Neuropathy YUICHI SAWAGUCHI, SATOSHI UENO, YUKIKO NISHIYMA, RYUTA YAMAZAKI and TAKESHI MATSUZAKI Yakult Central Institute for Microbiological Research, Yakult Honsha Co., Ltd., Kunitachi-shi, Tokyo, Japan Abstract. Peripheral neuropathy (PN) is a major dose- Microtubule-targeting agents (MTAs) have been clinically limiting side-effect of microtubule-targeting agents (MTAs), used since the 1960s for the effective treatment of leukemia, considered to be induced by inhibition of axonal lymphoma, and various solid tumors (1). MTAs are classified microtubules. Therefore, it was thought that a useful method roughly into the Vinca alkaloids (vincristine, vindesine, for predicting the frequencies of severe sensory-PN (FPN) vinorelbine) that de-stabilize or depolymerize microtubules, would be to evaluate the neurite-disrupting effects of MTAs. and the taxanes (paclitaxel, docetaxel) that polymerize Using neurite outgrowth from neuron-like cell lines, we microtubules, thus causing mitotic arrest. Meanwhile, MTAs comprehensively evaluated the neurite-disrupting effects of often induce neurotoxicities by having effects on neurons. several anti-cancer drugs including MTAs, and the Although it is still an open question how neurotoxicities are reversibility of the effects of MTAs. MTAs that induce PN clinically affected by MTAs, physiological and showed neurite-disrupting effects more strongly than MTAs histopathological studies in pre-clinical research showed this and anticancer drugs that do not induce PN, but the effects is due, at least in part, to the inhibition of axonal transport were not related to the FPN. On the other hand, MTAs with in neurons (2). Because of the excessive length of peripheral high FPN exhibited lower reversibility than those with low axons, MTAs are especially disruptive to axons forming FPN. These findings suggest that neurite-disrupting effects peripheral nerves and, therefore, induce peripheral are associated with the incidence of PN, and the reversibility neuropathy (PN). Generally, MTAs induce sensory PN more of the effects is associated with FPN. frequently than motor PN (3). Severe sensory-PN (grade 3/4 according to the National Cancer Institute Common Toxicity Microtubules are tubular polymers composed of α/β-tubulin Criteria scale) can be a dose-limiting factor of MTAs and heterodimers. The continuous equilibrium of microtubule significantly reduce QOL. assembly and disassembly makes the microtubules dynamic In Table I, we summarize the frequencies of severe structures that maintain cell shape, polarity, and motility; sensory-PN (FPNs) of MTAs in clinical trials. Vincristine provide a scaffold for cellular trafficking of proteins and and paclitaxel showed especially high FPNs (4-9). FPNs of organelles; and play an integral role in mitosis. Because docetaxel, vindesine, and vinorelbine are lower than those of microtubules and their dynamics are required for mitotic vincristine and paclitaxel (10-16). Indibulin, now in a phase spindle formation and chromosome separation during II clinical trial, was reported not to induce severe PN (17). mitosis, they are thought to be an important target for a These lines of clinical evidence indicate that FPNs are chemically diverse group of anticancer drugs that induce characteristic to each MTA, so it is desirable to discover mitotic arrest and cell death in vitro. MTAs with relatively low FPNs. To date, FPNs have been evaluated mainly using in vivo models in non-clinical studies (18); therefore, the establishment of an in vitro model in screening for drug discovery is anticipated. Correspondence to: Yuichi Sawaguchi, Yakult Central Institute for MTAs are considered to induce PN by interacting with Microbiological Research, Yakult Honsha Co., Ltd., Kunitachi-shi, axonal microtubules and then disrupting neurites. On the basis Tokyo, 186-8650, Japan. Tel: +81 425778960, Fax: +81 425773020, of this principle, in terms of in vitro methods for predicting e-mail: [email protected] FPNs, in order to evaluate the neurite-disrupting effects of Key Words: Peripheral neuropathy, microtubule-targeting agents, MTAs, it was thought to be useful to use neurite outgrowth neurite-distupting effects, in vitro model, PC-12 cells, SH-SY5Y evaluation from the PC-12 rat pheochromocytoma cell line cells. differentiated into neuron-like cells or the SH-SY5Y human 0250-7005/2015 $2.00+.40 6431 ANTICANCER RESEARCH 35: 6431-6438 (2015) Table I. Frequencies of peripheral neuropathy of microtubule-targeting agents in clinical trials. Agent FPNa, % Number of patients with Total number of First author grade 3/4 sensory PNb patients assessed Vincristine 18.4 37 201 Sarris (4), Thomas (5), O’Brien (6) Paclitaxel 15.3 51 333 Ibrahim (7), Gradishar (8), Kim (9) Docetaxel 6.3 24 382 Bonneterre (10), Tabernero (11), Jones (12) Vindesine 4.2 6 142 Eigentler (13) Vinorelbine 1.9 3 160 Fumoleau (14), Vogel (15), Zelek (16) Indibulin 0 0 14 Kuppens (17) aFPN: Frequencies of severe sensory peripheral neuropathy=percentage of patients with grade 3/4 sensory peripheral neuropathy. With regard to the MTAs reported in several clinical trials, the percentages were calculated from the total number of patients in all reports referred to. bPN: peripheral neuropathy neuroblastoma cell line (19, 20). However, there have been no Thermo Fisher Scientific, Nepean, ON, Canada). After 24 h, the reports regarding comprehensive evaluations of various MTAs medium was changed to low-serum (1% HS) medium, and PC-12 using these methods, so it was unclear how accurately the cells were treated with 50 ng/mL nerve growth factor (NGF; Merck Millipore, Nottingham, UK) for 72 h to induce neuronal neurite-disrupting effects reflect FPN. Meanwhile, it was differentiation and neurite outgrowth. Differentiated cells were then reported that the FPNs of MTAs became lower in proportion treated for 24 h with test drugs at several concentrations in the to the dosing interval in clinical trials (3). We, therefore, presence of NGF. hypothesized that neurites disrupted by MTAs re-extended SH-SY5Y cells were seeded in 96-well plates for 24 h, followed reversibly between dosages, which contributed to the recovery by culture for 72 h with 1 μM all-trans retinoic acid (ATRA) (Wako from PN. In the present study, we first evaluated the neurite- Chem. Co.) to induce neurite outgrowth. Then, the SH-SY5Y cells disrupting effects of MTAs using known methods and then were treated for 24 h with test drugs at several concentrations in the presence of ATRA. examined how well the effects correlated with FPN. Furthermore, we established a novel in vitro model for Assay for neurite-disrupting effects and reversibility of these effects. evaluating the reversibility of the neurite-disrupting effects and For evaluation of the neurite-disrupting effects, 300 cells in examined the correlation between this reversibility and FPN. triplicate wells were randomly chosen and the proportions of neurite-forming cells (neurite length >2 × cell body length) were Materials and Methods determined. Using the same cells, cell viability was assessed with WST-8 (Kishida Chemicals, Osaka, Japan) or CellTiter 96 Aqueous Materials. Paclitaxel, vincristine, vindesine, and vinorelbine were One Solution (Promega, Madison, WI, USA). The proportions of purchased from Sigma Aldrich (St. Louis, MO, USA). Docetaxel neurite-forming cells were corrected using the following equation: was purchased from Fluka (Buchs, Switzerland). Indibulin was (Correction value for the proportion of neurite-forming cells)= purchased from Tocris Bioscience (Bristol, UK). Doxorubicin was (proportion of neurite-forming cells scored by the evaluation of purchased from Wako Pure Chemical Industries, Ltd. (Tokyo, neurite-disrupting effects)/(cell viability). Japan). SN-38 and BI2536 were chemically synthesized by Yakult Thereafter, the concentrations of each test drug causing 50% Honsha (Tokyo, Japan). These drugs were dissolved in inhibition (IC50) of neurites were calculated from the correction dimethylsulfoxide (DMSO). The final concentration of DMSO in all values. treatments was adjusted to 0.1%. For evaluating the reversibility of the neurite-disrupting effects, after drug treatment, PC-12 and SH-SY5Y cells were cultured Cells and cell cultures. The PC-12 rat pheochromocytoma cell line without test drugs for another 48 h in DMEM containing NGF (PC- was obtained from Riken Cell Bank (Tsukuba, Japan) and cultured 12 cells) or RPMI1640 medium containing ATRA (SH-SY5Y cells). in Dulbecco’s modified Eagle’s medium (DMEM; Life After the culture, the proportions of neurite-forming cells were Technologies, Grand Island, NY, USA) with 10% (v/v) fetal bovine scored by the method mentioned above. serum (FBS) (Sigma-Aldrich) and 5% (v/v) horse serum (HS; MP Biomedicals, Aurora, OH, USA) at 37˚C in 5% CO2. HCT116 Cytotoxicity assay for cell survival. HCT116 cells were seeded in human colon cancer and SH-SY5Y human neuroblastoma cell line 96-well plates and test drugs were added to the cultures at several were both obtained from American Type Culture Collection and concentrations. After 96 h, cell viabilities were measured with WST- grown in RPMI1640 medium (Life Technologies) with 10% FBS at 8 and the concentrations of test drugs equivalent to the IC50 of cell 37˚C in 5% CO2. viabilities were calculated. Correlations between the proportion of
Load more

Recommended publications
  • Vincristine (Conventional): Drug Information
    Official reprint from UpToDate® www.uptodate.com ©2017 UpToDate® Vincristine (conventional): Drug information Copyright 1978-2017 Lexicomp, Inc. All rights reserved. (For additional information see "Vincristine (conventional): Patient drug information" and see "Vincristine (conventional): Pediatric drug information") For abbreviations and symbols that may be used in Lexicomp (show table) Special Alerts Vincristine Sulfate Safety Alert October 2015 Health Canada is notifying health care providers that certain lots of Hospira’s vincristine sulfate 1 mg/mL injection (DIN 02183013: 2 mL vial, list #7077A001; 5 mL vial, list #7082A001) have incorrect or outdated safety information on the inner/outer labels and package insert, which may increase the risk to patients and may result in significant patient harm requiring medical intervention. These warnings include: - Vincristine should only be administered by the intravenous (IV) route. Administration of vincristine by any other route can be fatal. - Syringes containing this product should be labeled “Warning - for IV use only.” - Extemporaneously prepared syringes containing this product must be packaged in an overwrap which is labeled “Do not remove covering until moment of injection. For IV use only - fatal if given by other routes.” - Contraindication of vincristine in patients with demyelinating Charcot-Marie-Tooth syndrome. - Potential risk of acute shortness of breath when vincristine is coadministered with mitomycin-C and GI toxicities including necrosis with administration of vincristine. Health care providers are requested to consult with the approved Canadian product monograph for vincristine sulfate 1 mg/mL for the most updated information. Consumers with questions should contact their health care provider for more information. ALERT: US Boxed Warning Experienced physician: Vincristine should be administered by individuals experienced in the administration of the drug.
    [Show full text]
  • Effect of Human Fibroblast Interferon on the Antiviral Activity of Mammalian Cells Treated with Bleomycin, Vincristine, Or Mitomycin C1
    [CANCER RESEARCH 43, 5462-5466. November 1983] Effect of Human Fibroblast Interferon on the Antiviral Activity of Mammalian Cells Treated with Bleomycin, Vincristine, or Mitomycin C1 Robert J. Suhadolnik,2 Yosuke Sawada,3 Maryann B. Flick, Nancy L. Reichenbach, and Joseph D. Mosca3 Department of Biochemistry, Temple University School of Medicine, Philadelphia, Pennsylvania 19140 ABSTRACT protein kinase (2,9,28,34,36). In addition to the use of interferon in the treatment of cancer (1, 11, 12, 29, 34), combination Bleomycin, vincristine, or mitomycin C, when added to HeLa chemotherapy of interferon and methotrexate, c/s-platinum diam- cells simultaneously with human fibroblast interferon (IFN-0), minedichloride, cyclophosphamide, or 1,3-bis(/i-chloroethyl)-1- caused a decrease in cell density and inhibited DMA synthesis nitrosourea on either tumor cells in culture or in leukemic mice compared with HeLa cells treated with IFN-/3 alone. However, has been reported (5, 7, 10, 25). Furthermore, Stolfi ef al. (37) the IFN-0-induced antiviral processes were unaffected by the reported recently that the administration of mouse interferon to presence of these drugs as determined by in vitro enzyme assays mice following the administration of 5-fluorouracil protected the and the development of the antiviral state in the intact HeLa cell. mice from mortality. Because it is possible to selectively inhibit HeLa cells treated with IFN-/Õalone or with IFN-/3 in combination proliferation of tumor cells with chemotherapeutic drugs, we with bleomycin, vincristine, or mitomycin C were able to induce reasoned that the ability of the normal cell to maintain the antiviral the double-stranded RNA-dependent adenosine triphos- phate:2',5'-oligoadenylic acid adenyltransferase (EC 2.2.2.-) and state might be adversely affected by such drugs and that the antiproliferative action of interferons might affect the activity of the double-stranded RNA-dependent protein kinase.
    [Show full text]
  • Metals and Metal Compounds in Cancer Treatment
    ANTICANCER RESEARCH 24: 1529-1544 (2004) Review Metals and Metal Compounds in Cancer Treatment BERNARD DESOIZE Laboratoire de Biochimie et de Biologie Moléculaire, EA 3306, IFR 53, Faculté de Pharmacie, 51 rue Cognacq-Jay, 51096 Reims cedex, France Abstract. Metals and metal compounds have been used in The importance of metal compounds in medicine is medicine for several thousands of years. In this review we undisputed, as can be judged by the use of compounds of summarized the anti-cancer activities of the ten most active antimony (anti-protozoal), bismuth (anti-ulcer), gold (anti- metals: arsenic, antimony, bismuth, gold, vanadium, iron, arthritic), iron (anti-malarial), silver (anti-microbial) and rhodium, titanium, gallium and platinum. The first reviewed platinum (anti-cancer) in the treatment of various diseases. metal, arsenic, presents the anomaly of displaying anti-cancer In terms of anti-tumour activity, a wide range of compounds and oncogenic properties simultaneously. Some antimony of both transition metals and main group elements have derivatives, such as Sb2O3, salt (tartrate) and organic been investigated for efficacy (1). The earliest reports on the compounds, show interesting results. Bismuth directly affects therapeutic use of metals or metal-containing compounds in Helicobacter pylori and gastric lymphoma; the effects of cancer and leukemia date from the sixteenth century. bismuth complexes of 6-mercaptopurine are promising. Superoxide dismutase inhibition leads to selective killing Gold(I) and (III) compounds show anti-tumour activities, of cancer cells in vitro and in vivo (2,3). As a consequence, although toxicity remains high. Research into the potential use reactive oxygen species (ROS) may not only be involved in of gold derivatives is still ongoing.
    [Show full text]
  • Eliminating Vincristine Administration Events
    Issue 37 October 2017 Eliminating vincristine administration events Issue: Despite the usually deadly consequences of accidentally administering the chemotherapy drug vincristine intrathecally, adverse events still occur, typically because some organizations still administer vincristine via syringe. The good news is that these events are happening less in the United States, mostly because of the efforts of leading national organizations to promote an effective prevention strategy that assures a mechanical barrier to intrathecal administration (into the subarachnoid space). The strategy involves diluting intravenous vincristine or other vinca alkaloids in a minibag that contains a volume that is too large for intrathecal administration (e.g., 25 mL for pediatric patients and 50 mL for adults), making it mechanically difficult to accidentally administer intrathecally.1 Vinca alkaloids (vinblastine, vinorelbine, vincristine, and vincristine liposomal) are chemotherapy drugs that are intended to be administered intravenously. If given intrathecally, vincristine is nearly always fatal and associated with an irreversible, painful ascending paralysis.2 When vinca alkaloids are injected intrathecally, destruction of the central nervous system occurs, radiating out from the injection site. The few survivors of this adverse event experienced devastating neurological damage.1 Part of the problem stems from ordering intravenous vincristine in conjunction with medications that are administered intrathecally via a syringe, such as methotrexate, cytarabine and hydrocortisone. In some adverse events, vincristine was mistakenly injected into the cerebrospinal fluid (CSF) of patients when the intent was to inject another intrathecal chemotherapy agent, such as methotrexate or cytarabine.3 Intravenous vincristine and other vinca alkaloids are dispensed from the pharmacy with explicit warning labels about their lethality if given intrathecally.
    [Show full text]
  • Vincristine Archive File
    Vincristine archive file Vincristine is a vinakaloid, which was first discovered 1958 in the tropical plant Catharanthus roseus, native in Madagascar. Its ability to inhibit the metaphase of the mitosis by suppressing the polymerization of the microtubule makes it very important as a chemotherapeutic agent, especially against non-Hodgkin lymphomas and Wilms' tumor. History: Vinblastine and Vincristine are bisindole alkaloids and both widely known for their use as antitumor drugs. In former times they were isolated in trace quantities from the leaves of Catharanthus roseus. Because of their importance in the medical field numerous researches were examining the structure, use and synthesis of Vinblastine, Vincristine and their derivates. Their biological effect to inhibit the microtubule formation and mitosis was and still is a very important part of medical cancer therapy. They were both among the first natural products whose structures were identified by X-ray crystallography and among the first for which X-ray analysis of a heavy atom derivative was used to establish their absolute configuration. ( 2) Timeline: 1958 Vinblastine was first discovered as an unexpected myelosuppressive agent by Noble, R. L., C. T. Beer, and J. H. Cutts during the search for an antidiabetic agent in Catharanthus roseus (myelosupression decreased activity of the bone marrow) 1959 independendently researchers from Eli Lilly (Johnson, I. S., J. G. Armstrong, M. Gorman, and J. P. Burnett, Jr.)discovered that the extracts of C. roseus Possesses activity against
    [Show full text]
  • Differential Activity of Vincristine and Vinblastine Against Cultured Cells1 ;
    [CANCER RESEARCH 44, 3307-3312, August 1984] Differential Activity of Vincristine and Vinblastine against Cultured Cells1 ; Peter J. Ferguson,2 J. Robert Phillips, Milada Seiner, and Carol E. Cass3 Cancer Research Group (McEachern Laboratory) [P. J. F., J. Ft. P., M. S., C. E. C.] and Department of Biochemistry [P. J. F., C. E. C.¡,University of Alberta, Edmonton, Alberta, Canada T6G 2H7 ABSTRACT determine if differential activity is related to differences in uptake4 or release of drug. Included were cells from these established Vincristine and vinblastine exhibit differential activity against lines: mouse neuroblastoma; mouse leukemia L1210; mouse tumors and normal tissues. In this work, a number of cultured lymphoma S49; HeLa; and human promyelocytic leukemia HL- cell lines were assayed for their sensitivity to the antiproliferative 60. Drug sensitivity in each cell line was determined by assaying and cytotoxic effects of the two drugs following short-term (4 hr) inhibition of proliferation during a continuous exposure to either or during continuous exposures. Differential activity was not drug or by assaying colony formation following a 24-hr exposure. seen when cells were subjected to continuous exposures. The Because of rapid loss of Vinca alkaloids from human serum concentrations of Vincristine and vinblastine, respectively, that following an i.v. bolus injection (11, 12,14, 17), the sensitivity of inhibited growth rates by 50% were: mouse leukemia L1210 cells to short-term (1- and 4-hr) exposures was also determined cells, 4.4 and 4.0 nw; mouse lymphoma S49 cells, 5 and 3.5 nM; for both drugs. Although there were differences in sensitivity to mouse neuroblastoma cells, 33 and 15 nw; HeLa cells, 1.4 and vincristine and vinblastine between cell lines, there was little or 2.6 nw; and human leukemia HL-60 cells, 4.1 and 5.3 nM.
    [Show full text]
  • Etoposide Compared with the Combination of Vincristine, Doxorubicin, and Cyclophosphamide in the Treatment of Small Cell Lung Cancer
    Thorax 1989;44:215-219 Thorax: first published as 10.1136/thx.44.3.215 on 1 March 1989. Downloaded from Etoposide compared with the combination of vincristine, doxorubicin, and cyclophosphamide in the treatment of small cell lung cancer M B McILLMURRAY, R J BIBBY, BE TAYLOR, L P ORMEROD, J R EDGE, R J WOLSTENHOLME, R F WILLEY, J F O'REILLY, N HORSFIELD, C E JOHNSON, C P MUSTCHIN, D BRISCOE From the Royal Lancaster Infirmary, Lancaster; Victoria Hospital, Blackpool; Royal Preston Hospital, Preston; Blackburn Royal Infirmary, Blackburn; Marsden Hospital, Burnley; Furness General Hospital, Cumbria; Cumberland Infirmary, Carlisle; and Royal Albert Edward Infirmary, Wigan ABSTRACT One hundred and three patients with small cell lung carcinoma were stratified according to stage ofdisese (47 limited disease, 56 extensive disease) and then randomised to receive etoposide 300 mg/m2 alone for two days or a combination (VAC) of vincristine 1 mg/m2, doxorubicin (Adriamycin) 50 mg/m2, and cyclophosphamide 1000 mg/m2. The drugs were given at three week intervals. Patients were assessed after three cycles of treatment and continued with the same regimen ifin complete remission and with the alternative regimen ifin partial remission; they were withdrawn if the disease had progressed. Twenty four patients (23%) achieved complete remission and this copyright. occurred more often when patients were receiving VAC (19 of82) than etoposide (5 of75). There was no difference, however, in overall survival between those initially treated with etoposide and those having combination chemotherapy, whether for limited disease (both 8 months) or extensive disease (7 and 5 5 months).
    [Show full text]
  • Eldisine * (Vindesine Sulphate)
    PACKAGE LEAFLET: INFORMATION FOR THE USER 2. WHAT YOU NEED TO KNOW BEFORE YOU USE ELDISINE your bone marrow. These cells divide quickly to make new blood Do not use Eldisine if you: cells. Your doctor or nurse will take samples of your blood when Eldisine * • are allergic to vindesine sulphate or any of the other ingredients you are treated with Eldisine. The hospital’s laboratory will then (Vindesine Sulphate) in Eldisine (see section 6 – Contents of the pack and other count the numbers of different types of blood cells (platelets, white information) cells and red cells). Your doctor may decide to change the dose or Read all of this leaflet carefully before you start taking this • suffer from any disease affecting the nerves or muscles (such as put off treating you if your blood cell counts are too low. Your blood medicine. Charcot-Marie-Tooth syndrome) cell counts soon improve as the bone marrow makes new cells. - Keep this leaflet. You may need to read it again. • have a bacterial infection. A lot of injections (more than one a week) may cause more side- - If you have any further questions, ask your doctor or pharmacist. Warnings and precautions effects. - This medicine has been prescribed for you. Do not pass it on to Talk to your doctor or pharmacist before using Eldisine if you: Eldisine works by sticking to certain molecules in dividing cells to others. It may harm them, even if their signs of illness are the • are having radiotherapy in the liver area stop the cells dividing. It also sticks to the same sort of molecule in same as yours.
    [Show full text]
  • Chemotherapy and Polyneuropathies Grisold W, Oberndorfer S Windebank AJ European Association of Neurooncology Magazine 2012; 2 (1) 25-36
    Volume 2 (2012) // Issue 1 // e-ISSN 2224-3453 Neurology · Neurosurgery · Medical Oncology · Radiotherapy · Paediatric Neuro- oncology · Neuropathology · Neuroradiology · Neuroimaging · Nursing · Patient Issues Chemotherapy and Polyneuropathies Grisold W, Oberndorfer S Windebank AJ European Association of NeuroOncology Magazine 2012; 2 (1) 25-36 Homepage: www.kup.at/ journals/eano/index.html OnlineOnline DatabaseDatabase FeaturingFeaturing Author,Author, KeyKey WordWord andand Full-TextFull-Text SearchSearch THE EUROPEAN ASSOCIATION OF NEUROONCOLOGY Member of the Chemotherapy and Polyneuropathies Chemotherapy and Polyneuropathies Wolfgang Grisold1, Stefan Oberndorfer2, Anthony J Windebank3 Abstract: Peripheral neuropathies induced by taxanes) immediate effects can appear, caused to be caused by chemotherapy or other mecha- chemotherapy (CIPN) are an increasingly frequent by different mechanisms. The substances that nisms, whether treatment needs to be modified problem. Contrary to haematologic side effects, most frequently cause CIPN are vinca alkaloids, or stopped due to CIPN, and what symptomatic which can be treated with haematopoetic taxanes, platin derivates, bortezomib, and tha- treatment should be recommended. growth factors, neither prophylaxis nor specific lidomide. Little is known about synergistic neu- Possible new approaches for the management treatment is available, and only symptomatic rotoxicity caused by previously given chemo- of CIPN could be genetic susceptibility, as there treatment can be offered. therapies, or concomitant chemotherapies. The are some promising advances with vinca alka- CIPN are predominantly sensory, duration-of- role of pre-existent neuropathies on the develop- loids and taxanes. Eur Assoc Neurooncol Mag treatment-dependent neuropathies, which de- ment of a CIPN is generally assumed, but not 2012; 2 (1): 25–36. velop after a typical cumulative dose. Rarely mo- clear.
    [Show full text]
  • SAVACM Protocol
    BC Cancer Protocol Summary for the Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria using vinCRIStine, DOXOrubicin, Cyclophosphamide and Mesna Protocol Code SAVACM Tumour Group Sarcoma Contact Physician Dr. Christine Simmons ELIGIBILITY: . Ewing’s sarcoma/peripheral neuroectodermal tumour or rhabdomyosarcoma in pelvic sites or pediatric type small round blue cell tumours in patients for whom alternating protocol is not appropriate where treatment includes pelvic radiotherapy . Patients with hematuria due to ifosfamide or cyclophosphamide . Good performance status . Adequate bone marrow, liver and kidney function TESTS: . Baseline and before each treatment: CBC and diff, platelets, creatinine, bilirubin, ALT, alkaline phosphatase, GGT, LDH . Urine dipstick for blood before each treatment and every 8 hours during treatment – if positive at any time, notify doctor and send urine sample for urinalysis and verification and accurate determination - refer to supportive care protocol SCMESNA (follow SCMESNA (SAVACM) preprinted order) . If clinically indicated: ECG PREMEDICATIONS: . Antiemetic protocol for highly emetogenic chemotherapy protocols (see SCNAUSEA) . LORazepam 1 mg SL every 4 to 6 hours as needed . prochlorperazine 10 mg PO every 4 to 6 hours as needed . nabilone 1 mg PO every 6 to 8 hours as needed TREATMENT: . Repeat every 3 weeks. SAVACM is not given during radiotherapy; omit DOXOrubicin and continue with vinCRIStine, cyclophosphamide and mesna. BC Cancer Protocol Summary SAVACM Page 1 of 3 Activated: N/A Revised: 1 Apr 2021 (prochlorperazine route) Warning: The information contained in these documents are a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment.
    [Show full text]
  • Vinorelbine Inj. USP
    VINORELBINE INJECTION USP survival between the 2 treatment groups. Survival (Figure 1) for patients receiving Vinorelbine Injection USP pIus cisplatin was Patients treated with Vinorelbine Injection USP should be frequently monitored for myelosuppression both during and after significantly better compared to the-patients who received single-agent cisplatin. The results of this trial are summarized in Table 1. therapy. Granulocytopenia is dose-limiting. Granulocyte nadirs occur between 7 and 10 days after dosing with granulocyte count PRESCRIBING INFORMATION Vinorelbine Injection USP plus Cisplatin versus Vindesine plus Cisplatin versus Single-Agent Vinorelbine Injection USP: In a recovery usually within the following 7 to 14 days. Complete blood counts with differentials should be performed and results large European clinical trial, 612 patients with Stage III or IV NSCLC, no prior chemotherapy, and WHO Performance Status of 0, 1, reviewed prior to administering each dose of Vinorelbine Injection USP. Vinorelbine Injection USP should not be administered to WARNING: Vinorelbine Injection USP should be administered under the supervision of a physician experienced in the use of or 2 were randomized to treatment with single-agent Vinorelbine Injection USP (30 mg/m2/week), Vinorelbine Injection USP (30 patients with granulocyte counts <1,000 cells/mm3. Patients developing severe granulocytopenia should be monitored carefully for cancer chemotherapeutic agents. This product is for intravenous (IV) use only. Intrathecal administration of other vinca alkaloids mg/m2/week) plus cisplatin (120 mg/m2 days 1 and 29, then every 6 weeks), and vindesine (3 mg/m2/week for 7 weeks, then every evidence of infection and/or fever. See DOSAGE AND ADMINISTRATION for recommended dose adjustments for granulocytopenia.
    [Show full text]
  • DRUG NAME: Vinorelbine
    Vinorelbine DRUG NAME: Vinorelbine SYNONYM(S): Vinorelbine tartrate, VRL, VNL, NVB COMMON TRADE NAME(S): NAVELBINE® CLASSIFICATION: Mitotic inhibitor Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Vinorelbine is a semisynthetic vinca alkaloid derived from vinblastine. Vinca alkaloids such as vincristine and vinblastine are originally derived from periwinkle leaves (vinca rosea).1 Vinorelbine inhibits cell growth by binding to the tubulin of the mitotic microtubules.2 Like other mitotic inhibitors, vinorelbine also promotes apoptosis in cancer cells.1 In vitro vinorelbine shows both multidrug and non-multidrug resistance.2 Microtubules are present in mitotic spindles, neuronal axons, and other cells. Inhibition of mitotic microtubules appears to correlate with antitumour activity, while inhibition of axonal microtubules seems to correlate with neurotoxicity. Compared to vincristine and vinblastine, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.3 Vinorelbine is a radiation-sensitizing agent.4 It is cell cycle phase-specific (M phase).2 PHARMACOKINETICS: Interpatient variability moderate to large interpatient variability5,6 Distribution Widely distributed in the body, mostly in spleen, liver, kidneys, lungs, thymus; moderately in heart, muscles; minimally in fat, brain, bone marrow.3 High levels found in both normal and malignant lung tissue, with slow diffusion out of tumour tissue.1 cross
    [Show full text]